Logo
W

WuXi Biologics

2488 employees

WuXi Biologics is a open-access technology platform company offering end-to-end solutions to empower organizations to discover and develop.

Investor insights

Sectors invested in

Biotechnology6
Medical3
Biopharma3
biotechnology and veterinary medicine2
Health Care2
Therapeutics2
Veterinary2
autoimmune2
Oncology2
biotech2

Funding rounds participated in

$15M sweet spot round size

Most of their 7 investments are in rounds between $14M and $40M

Basic info

Industry

pharmaceutical manufacturing

Sectors

Pharmaceutical
Biologics discovery service
protein production
vaccine manufacturing
biopharmaceuticals
Bioprocess CMC
Monoclonal Antibodies (mAbs)
Biologics GMP Manufacturing
Health Care
Biologics conjugation
biotherapeutics
Formulation Development
analytical services
continuous manufacturing
Biosafety
Analytical Characterization
vaccine development
antibody discovery
antibody manufacturing
Cell Line Development
Cell Culture and Purification Process Development

Date founded

2010

Investments made

I

Innolake Biopharm raised $14M on June 5, 2023

Investors: WuXi Biologics

D

Duality Biologics raised $90M on May 19, 2021

Investors: 华盖资本有限责任公司, GREEN PINE CAPITAL PARTNERS, Lilly Asia Ventures and WuXi Biologics

I

Innolake Biopharm raised $46M on January 1, 2021

Investors: 华盖资本有限责任公司, CDH Investments and WuXi Biologics

I

Invetx raised $10M on September 30, 2020

Investors: Anterra Capital, Casdin Capital, LLC, AbCellera and WuXi Biologics

I

Invetx raised $15M on February 24, 2020

Investors: Anterra Capital, AbCellera and WuXi Biologics

U

Undisclosed raised $40M on May 21, 2019

Investors: Lilly Asia Ventures, RA Capital Management, L.P., Viking Global Investors and WuXi Biologics

D

Duoning raised $15M on April 23, 2019

Investors: WuXi Biologics

FAQ